{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000291","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.209239+00:00","generated_at":"2026-05-27T22:24:55.494131+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xilio reports 27% response rate for vilastobart + atezolizumab in MSS CRC Phase 2 trial","bullets":["27% preliminary ORR (3 PRs, 2 confirmed) in MSS CRC patients without liver metastases as of Jan 13, 2025 cutoff.","Responses accompanied by decreases in CEA and ctDNA levels and clinical symptom improvement.","Safety: well-tolerated; 5% colitis, low Grade 3/4 irAEs, no treatment-related deaths.","Heavily pre-treated population: 70% had ≥3 prior lines of therapy.","Company plans to seek partnerships; expects to report updated Phase 2 data mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000291","json":"https://secwatch.observer/filing/0001558370-25-000291.json","markdown":"https://secwatch.observer/filing/0001558370-25-000291.md","text":"https://secwatch.observer/filing/0001558370-25-000291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025000291/0001558370-25-000291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025000291/xlo-20250121x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:24:55.494131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}